hotspot -WSS

hotspot

author：focus 2025-09-30 15:15:21 - browse：6

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Elon Musk announces 'temporary limits' for reading Twitter posts

entertainment

WSS

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Leon Gautier, last member of French D

A timeline of the missing Titanic tourist submersible

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

FDA advisers vote against ALS treatment from BrainStorm

PlayStation controller and acoustic messaging: How the missing Titanic tourist sub works

Wikipedia

hotspot

focus

Walensky prepares to leave CDC — and Congress — behind

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Duchenne breakthrough therapy leaves behind pioneering families

Why do women spend more than men on medical expenses?

How to save PrEP access — and even expand it

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

Walensky prepares to leave CDC — and Congress — behind

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Walensky prepares to leave CDC — and Congress — behind

Senator probes 340B programs at Cleveland Clinic, Bon Secours

leisure time

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Listen: Who gets the credit for GLP

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

10 states plan to sue EPA over standards for residential wood

Health tech startups drop sharply from 2021 highs

Address the ethical violations that led to 'Three Identical Strangers'

hotspot

explore

entertainment

focus